| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |